Ameriprise’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.2M Sell
267,328
-257,994
-49% -$1.34M ﹤0.01% 3211
2025
Q4
$3.23M Sell
525,322
-17,750
-3% -$129K ﹤0.01% 2743
2025
Q3
$3.93M Buy
543,072
+126,630
+30% +$752K ﹤0.01% 2605
2025
Q2
$2.21M Buy
416,442
+217,796
+110% +$1.29M ﹤0.01% 2898
2025
Q1
$1.76M Sell
198,646
-11,269
-5% -$135K ﹤0.01% 2959
2024
Q4
$2.88M Sell
209,915
-21,904
-9% -$404K ﹤0.01% 2718
2024
Q3
$6.35M Sell
231,819
-21,599
-9% -$585K ﹤0.01% 2206
2024
Q2
$6.2M Sell
253,418
-9,539
-4% -$209K ﹤0.01% 2142
2024
Q1
$5.61M Sell
262,957
-8,007
-3% -$172K ﹤0.01% 2282
2023
Q4
$5.19M Buy
270,964
+863
+0.3% +$14.9K ﹤0.01% 2322
2023
Q3
$4.33M Sell
270,101
-27,052
-9% -$515K ﹤0.01% 2392
2023
Q2
$6.89M Sell
297,153
-13,740
-4% -$300K ﹤0.01% 2098
2023
Q1
$7.22M Sell
310,893
-7,749
-2% -$157K ﹤0.01% 2036
2022
Q4
$4.62M Sell
318,642
-161,485
-34% -$3.01M ﹤0.01% 2340
2022
Q3
$9.16M Sell
480,127
-222,091
-32% -$5.1M ﹤0.01% 1758
2022
Q2
$12.8M Sell
702,218
-18,208
-3% -$378K ﹤0.01% 1539
2022
Q1
$18.2M Buy
720,426
+5,562
+0.8% +$142K 0.01% 1434
2021
Q4
$19.7M Buy
714,864
+60,795
+9% +$1.76M 0.01% 1417
2021
Q3
$21.1M Buy
654,069
+306,339
+88% +$10.2M 0.01% 1221
2021
Q2
$10.6M Buy
347,730
+1,061
+0.3% +$30.7K ﹤0.01% 1889
2021
Q1
$10.6M Buy
346,669
+18,699
+6% +$531K ﹤0.01% 1845
2020
Q4
$6.49M Sell
327,970
-120,622
-27% -$1.95M ﹤0.01% 2088
2020
Q3
$5.85M Buy
448,592
+78,527
+21% +$994K ﹤0.01% 1966
2020
Q2
$4.2M Sell
370,065
-2,988
-0.8% -$42.4K ﹤0.01% 2186
2020
Q1
$5.34M Sell
373,053
-100,475
-21% -$2.12M ﹤0.01% 1866
2019
Q4
$12.9M Buy
473,528
+26,979
+6% +$742K 0.01% 1541
2019
Q3
$12.8M Buy
446,549
+331
+0.1% +$9.64K 0.01% 1498
2019
Q2
$12.4M Sell
446,218
-38,164
-8% -$1.08M 0.01% 1560
2019
Q1
$16.1M Sell
484,382
-14,660
-3% -$446K 0.01% 1293
2018
Q4
$14.5M Sell
499,042
-4,150
-0.8% -$149K 0.01% 1290
2018
Q3
$23.1M Buy
503,192
+64,431
+15% +$2.86M 0.01% 1186
2018
Q2
$16.4M Buy
438,761
+1,095
+0.3% +$37K 0.01% 1323
2018
Q1
$12.9M Buy
437,666
+15,490
+4% +$524K 0.01% 1454
2017
Q4
$14.5M Buy
422,176
+6,359
+2% +$215K 0.01% 1310
2017
Q3
$15M Sell
415,817
-1,571
-0.4% -$44.8K 0.01% 1260
2017
Q2
$10.8M Buy
417,388
+53,263
+15% +$1.13M 0.01% 1494
2017
Q1
$6.99M Buy
+364,125
New +$6.45M ﹤0.01% 1779
2016
Q3
Sell
-51,592
Closed -$1.58M 3816
2016
Q2
$1.58M Buy
51,592
+43,663
+551% +$1.52M ﹤0.01% 2643
2016
Q1
$297K Sell
7,929
-694
-8% -$26.1K ﹤0.01% 3372
2015
Q4
$372K Sell
8,623
-62,372
-88% -$2.64M ﹤0.01% 3392
2015
Q3
$2.66M Sell
70,995
-37,636
-35% -$1.34M ﹤0.01% 2456
2015
Q2
$3.69M Sell
108,631
-37,432
-26% -$1.27M ﹤0.01% 2345
2015
Q1
$5.17M Sell
146,063
-105,588
-42% -$3.78M ﹤0.01% 2094
2014
Q4
$8.57M Sell
251,651
-51,696
-17% -$1.83M 0.01% 1633
2014
Q3
$11.7M Buy
303,347
+103,557
+52% +$3.86M 0.01% 1332
2014
Q2
$7.78M Buy
199,790
+57,187
+40% +$2.13M ﹤0.01% 1744
2014
Q1
$4.88M Sell
142,603
-114,166
-44% -$3.54M ﹤0.01% 2037
2013
Q4
$5.39M Sell
256,769
-427,745
-62% -$10.8M ﹤0.01% 1950
2013
Q3
$16.1M Sell
684,514
-12,738
-2% -$362K 0.01% 1126
2013
Q2
$18.7M Buy
+697,252
New +$20.2M 0.01% 1017

Other funds holding MYGN

Ameriprise's MYGN Position: Q1 2026 in Review

Ameriprise reduced its Myriad Genetics (MYGN) stake by 49% in Q1 2026, selling an estimated $1.34M and leaving 267,328 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

Ameriprise first reported a position in MYGN in Q2 2013 and has held it in 50 quarters since. The position peaked at $23.1M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Ameriprise held 267,328 shares of Myriad Genetics worth $1.2M as of Q1 2026.
  • Ameriprise sold 257,994 Myriad Genetics shares in Q1 2026, an estimated $1.34M.
  • Myriad Genetics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3211 holding.
  • Ameriprise first reported a position in Myriad Genetics in Q2 2013 and has held it in 50 quarters since.
  • Ameriprise's Myriad Genetics position peaked at $23.1M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.